5-Day Rally Sends Apellis Pharmaceuticals Stock Up 139%
Apellis Pharmaceuticals (APLS) – a developer of complement-inhibiting therapies for autoimmune diseases – hit a 5-day winning streak, with cumulative gains over this period amounting to 139%. The company’s market cap has surged by about $3.0 Bil over the last 5 days and currently stands at $5.1 Bil.
Is this an opportunity or a trap? There is a near-equal mix of good and bad in APLS stock given its overall Moderate operating performance and financial condition. But keeping in mind its High valuation, we think that the stock is Unattractive (For details, see Buy or Sell APLS).
But here is the interesting part. You are reading about this 139% move after it happened. The market has already priced in the news. To catch the next winner before the headlines, you need predictive signals, not notifications. High Quality Portfolio is based on an architecture that includes such signals.
Returns vs S&P 500
- How To Earn 9.2% Yield While Waiting to Buy LLY 30% Cheaper
- Could Accenture Stock’s Cash Flow Spark the Next Rally?
- Years of Rewards: $35 Bil From Charter Communications Stock
- McDonald’s Stock Capital Return Hits $35 Bil
- Palo Alto Networks Stock at Support Zone – Bargain or Trap?
- Super Micro Computer Stock Pulls Back to Support – Smart Entry?
The following table summarizes the return for APLS stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | APLS | S&P 500 |
|---|---|---|
| 1D | 0.5% | 0.4% |
| 5D (Current Streak) | 139.4% | 3.8% |
| 1M (21D) | 101.6% | -3.2% |
| 3M (63D) | 57.1% | -3.6% |
| YTD 2026 | 61.7% | -3.4% |
| 2025 | -21.3% | 16.4% |
| 2024 | -46.7% | 23.3% |
| 2023 | 15.8% | 24.2% |
However, big gains can follow sharp reversals – but how has APLS behaved after prior drops? See APLS Dip Buyer Analysis to learn more.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 89 S&P constituents with 3 days or more of consecutive gains and 24 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 10 | 20 |
| 4D | 41 | 3 |
| 5D | 35 | 1 |
| 6D | 1 | 0 |
| 7D or more | 2 | 0 |
| Total >=3 D | 89 | 24 |
Key Financials for Apellis Pharmaceuticals (APLS)
Last 2 Fiscal Years:
| Metric | FY2024 | FY2025 |
|---|---|---|
| Revenues | $781.4 Mil | $1.0 Bil |
| Operating Income | $-165.0 Mil | $55.4 Mil |
| Net Income | $-197.9 Mil | $22.4 Mil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ3 | 2025 FQ4 |
|---|---|---|
| Revenues | $458.6 Mil | $199.9 Mil |
| Operating Income | $223.2 Mil | $-51.1 Mil |
| Net Income | $215.7 Mil | $-59.0 Mil |
While APLS stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.